PHASE 1 STUDY IN HEALTHY ADULTS OF THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF ALPN-303, A DUAL BAFF/APRIL ANTAGONIST FOR THE TREATMENT OF AUTOIMMUNE GLOMERULONEPHRITIDES
Back
Abstract Number
WCN23-0466
Categories
AKI, Electrolytes, Acid-base Disorders, Tropical Diseases, RPGN and Pregnancy
Topic - Chronic Kidney Disease, Hypertension, Diabetes and CVD
Topic - AKI, Electrolytes, Acid-base Disorders, Tropical Diseases, RPGN and Pregnancy
Clinical Glomerulonephritis
Topic - Kidney Failure (Former ESKD), incl. Dialysis, Transplantation, Conservative Care
Topic - Special Covid-19
Topic - Education
Abstract Title
PHASE 1 STUDY IN HEALTHY ADULTS OF THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF ALPN-303, A DUAL BAFF/APRIL ANTAGONIST FOR THE TREATMENT OF AUTOIMMUNE GLOMERULONEPHRITIDES
Co-authors
Dillon, S.R.(1);Davies, R.(1);Lickliter, J.D.(2);Mclendon, K.(3);Manjarrez, K.L.(1);Smith, A.(4);Lessig, M.C.(4);Blanchfield, L.(5);Sanderson, R.J.(6);Chunyk, A.G.(6);Enstrom, A.(1);Blair , T.(5);Hany Zayed, H.Z.(7);Li, J.(1)*;Peng, S.L.(8)
ie:
Azwin Z.1, Siti Y.1, John D.2
Institution
(1)Alpine Immune Sciences Inc., Translational Medicine, Seattle, United States;(2)Nucleus Network, Research, Melbourne, Australia;(3)Nucleus Network, Research, Brisbane, Australia;(4)Alpine Immune Sciences Inc., Clinical Operations, Seattle, United States;(5)Alpine Immune Sciences Inc., Translational Sciences, Seattle, United States;(6)Alpine Immune Sciences Inc., Bioanalytical Sciences, Seattle, United States;(7)Alpine Immune Sciences Inc., Data Sciences, Seattle, United States;(8)Alpine Immune Sciences Inc., R And D, Seattle, United States
E-Poster
https://storage.unitedwebnetwork.com/files/1041/101c2f167571f8bba596b66f06914686.pdf
Audio File
if any